Advertisement

Topics

Ironwood Pharmaceuticals, Inc. & Astellas Pharma Inc. Company Profile

14:16 EDT 26th March 2019 | BioPortfolio

Ironwood Pharmaceuticals (NASDAQ: IRWD) is a commercial biotechnology company focused on creating medicines that make a difference for patients, building value for our fellow shareholders, and empowering our passionate team. We are commercializing two innovative primary care products: linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), and lesinurad, which is approved to be taken with a xanthine oxidase inhibitor (XOI) for the treatment of hyperuricemia associated with uncontrolled gout. We are also advancing a pipeline of internally and externally generated innovative product candidates in areas of significant unmet need, including uncontrolled gastroesophageal reflux disease and vascular and fibrotic diseases. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. For more information, please visit www.ironwoodpharma.com or www.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both these locations.


News Articles [1593 Associated News Articles listed on BioPortfolio]

M&As this week: Astellas Pharma, Taisho Pharmaceuticals, AMAG Pharmaceuticals

Astellas Pharma has completed the acquisition of Potenza Therapeutics for $405m. Astellas made an upfront payment of $164.6m and has...Read More... The post M&As this week: Astellas Pharma, Taish...

Ironwood Pharma gets Chinese marketing approval for Linzess to treat irritable bowel syndrome with constipation

AstraZeneca announced that its partner Ironwood Pharmaceuticals, Inc has received marketing authorisation from the National Medical Products Administration (NMPA) for Linzess (linaclotide) in China fo...

Astellas Pharma Inc. Strategy, SWOT and Corporate Finance Report [Report Updated: 12102018] Prices from USD $175

Astellas Pharma Inc. Strategy, SWOT and Corporate Finance ReportSummaryAstellas Pharma Inc. Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. Th...

Ironwood/AstraZeneca Approved to Market IBS-C Treatment in China

Ironwood Pharma reported that China approved its treatment for irritable bowel syndrome with constipation (IBS-C). Ironwood, which is partnering the China marketing of the drug with AstraZeneca, expec...

Ironwood and Allergan Announce Settlement with Mylan Resolving LINZESS (linaclotide) Patent Litigation

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Mylan Pharmaceuticals, Inc. (NASDAQ: MYL) resolving pat...

Ironwood and Allergan settle Linzess patent litigation with Mylan

Ironwood Pharmaceuticals and Allergan have entered an agreement with Mylan Pharmaceuticals to settle patent litigations over generic versions of Linzess...Read More... The post Ironwood and Allergan s...

FDA fast-tracks Ironwood's heart failure candidate

Ironwood Pharmaceuticals' IW-1973, or praliciguat, indicated to treat patients with heart failure with preserved ejection fra -More- 

Allergan/Ironwood settle generic Linzess patent litigation with Mylan

Ironwood Pharmaceuticals Inc. and Allergan PLC have settled patent litigation with Mylan Pharmaceuticals Inc. surrounding Mylan’s abbreviated new drug applications for generic Linzess (linaclotide)....

Drugs and Medications [75 Associated Drugs and Medications listed on BioPortfolio]

Fluoxetine hydrochloride [northwind pharmaceuticals]

NA

Fluoride [mayne pharma inc]

Fluoride Chewable Tablets 0.5 mg

Fluoride [mayne pharma inc]

Fluoride Chewable Tablets 1 mg

Valsartan and hydrochlorothiazide [northwind pharmaceuticals]

NA

Urea [mayne pharma inc.]

Rx Only 45% Urea Nail Gel In a vehicle containing Camphor, Eucalyptus Oil and Menthol )

PubMed Articles [167 Associated PubMed Articles listed on BioPortfolio]

Swimming activity in zebrafish larvae exposed to veterinary antiparasitic pharmaceuticals.

Veterinary antiparasitic pharmaceuticals have been detected in surface waters and several of these pharmaceuticals act on the nervous system on the target organisms implying that neurological effects ...

Insight into the distribution of pharmaceuticals in soil-water-plant systems.

Pharmaceuticals in agricultural soils originating from irrigation with treated wastewater and land-applied biosolids can enter field crops. However, little is known about the role of pore water in pla...

U.S. Emergency Department Visits Resulting From Nonmedical Use of Pharmaceuticals, 2016.

National data on morbidity from nonmedical use of pharmaceuticals are limited. This study used nationally representative, public health surveillance data to characterize U.S. emergency department visi...

Chiral pharmaceuticals: Environment sources, potential human health impacts, remediation technologies and future perspective.

Chiral pharmaceuticals (CPs), including non-steroid anti-inflammatory drugs (NSAIDs), β-blockers and some herbicide and pesticides, are widely used in aquaculture, clinical treatment and many other f...

Assessment of 83 pharmaceuticals in WWTP influent and effluent samples by UHPLC-MS/MS: Hourly variation.

The removal efficiency of pharmaceuticals in wastewater treatment plants (WWTPs) is variable and some of these compounds pass these plants almost intact and others presenting a removal efficiency clos...

Clinical Trials [316 Associated Clinical Trials listed on BioPortfolio]

A Bioequivalence Study of Dexlansoprazole From Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant 60 mg Delayed Release (DR) Capsules (Takeda Pharmaceuticals America Inc., USA)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Dexlansoprazole from Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant...

To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)

This is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Tacrolimus Ointment, 0.1% (Glenmark Pharmac...

Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition

The primary objective is to determine clinical bioequivalence of Amphotericin B liposome for injection of Auromedics Pharma LLC, USA and AmBisome (Amphotericin B) liposome for injection of...

Bioequivalence Study of Tacrolimus 1 mg Capsule Under Fed Condition

The objective of the study is to demonstrate bioequivalence between Test Product (A): Tacrolimus Capsules 1 mg, manufactured by Panacea Biotec Limited, India and the corresponding Referenc...

Bioequivalence Study of Tacrolimus 5 mg Capsule Under Fed Condition

The objective of the study is to demonstrate bioequivalence between Test Product (A): Tacrolimus Capsules 5 mg, manufactured by Panacea Biotec Limited, India and the corresponding Referenc...

Companies [2132 Associated Companies listed on BioPortfolio]

Astellas Pharma Canada, Inc.

Astellas Pharma Europe Ltd., located in the UK, is the European Headquarters of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the he...

Astellas Pharma Inc.

Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals...

Astellas Pharma Global Development

Astellas Pharma Global Development, located in Deerfield, Illinois, is a group company of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of peo...

Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc.

Ironwood Pharmaceuticals (NASDAQ: IRWD) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholde...

Almirall, S.A. and Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwood's GC-C agon...

More Information about "Ironwood Pharmaceuticals, Inc. & Astellas Pharma Inc." on BioPortfolio

We have published hundreds of Ironwood Pharmaceuticals, Inc. & Astellas Pharma Inc. news stories on BioPortfolio along with dozens of Ironwood Pharmaceuticals, Inc. & Astellas Pharma Inc. Clinical Trials and PubMed Articles about Ironwood Pharmaceuticals, Inc. & Astellas Pharma Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ironwood Pharmaceuticals, Inc. & Astellas Pharma Inc. Companies in our database. You can also find out about relevant Ironwood Pharmaceuticals, Inc. & Astellas Pharma Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Irritable Bowel Syndrome IBS
Irritable bowel syndrome (IBS) is a common but poorly understood chronic (long-term) condition where the normal functions of the bowel are disrupted. Symptoms of IBS include abdominal pain or discomfort, changes in bowel habits and bloated feelings. ...


Corporate Database Quicklinks



Searches Linking to this Company Record